Arcus Biosciences, Inc. Appoints Steven Chan as Principal Financial Officer, Effective January 12, 2019
January 04, 2019 at 07:06 pm IST
Share
On December 31, 2018, Jennifer Jarrett, Arcus Biosciences, Inc.'s Chief Financial and Operating Officer, notified the Company of her intent to resign effective January 11, 2019. On January 3, 2019, the Board of Directors of the Company appointed Ms. Jarrett to the Board as a Class III non-employee director effective January 12, 2019. Ms. Jarrett was appointed to a newly created vacancy resulting from an increase in the size of the Board from six (6) to seven (7) directors. In connection with Ms. Jarrett's resignation, Steven Chan, the Company's Vice President of Finance and principal accounting officer, has been appointed principal financial officer effective January 12, 2019. Mr. Chan has served as Vice President, Finance and Corporate Controller since April 2017 and Principal Accounting Officer since December 2017. Before that, from November 2014 to March 2017, he served as the Vice President of Finance and Corporate Controller at MyoKardia, Inc. where he helped lead the company to an initial public offering in 2015.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
ARCUS BIOSCIENCES, INC. 
